Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 10/20 | 0.60 |
| ▸ | TNKS | O95271 | 9/20 | 0.60 |
| ▸ | PARP1 | P09874 | 6/20 | 0.60 |
| ▸ | GUSB | P08236 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12758425 | 0.89 | ALDH1A1 (0.73) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL6695759 | 0.80 | TNKS2 (0.81) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL24743603 | 0.78 | PARP1 (0.62) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL6122044 | 0.78 | TNKS2 (0.56) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL10709261 | 0.78 | NPC1 (1.00) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL29764050 | 0.78 | NPC1 (1.00) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL21843249 | 0.78 | ALDH1A1 (0.63) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL30169443 | 0.78 | NPC1 (1.00) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL29484635 | 0.78 | NPC1 (0.60) | NPC1RAB9AALDH1A1LMNAGAA | |
| SCHEMBL11570157 | 0.78 | NPC1 (0.60) | NPC1RAB9AALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966184-B1 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-08-25 | — | — | EP | disclosed |
| US-20090306102-A1 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2009-12-10 | — | — | US | disclosed |
| EP-1966184-A2 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071632-A2 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2007-06-28 | — | — | WO | disclosed |
| WO-2004065392-A1 | CONDENSED PYRIDINES AND PYRIMIDINES AND THEIR USE AS ALK-5 RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306102-A1 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | KCNJ2, KCNQ1, KCNK2 | NPC1 1135/4885RAB9A 1695/4885ALDH1A1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.